Dosing device in new Children’s Panadol 1-5 years suspension

GlaxoSmithKline (GSK) is disappointed with the decision made on May 28 2013 by the Federal Court (Justice Rares), to grant an interim injunction over the dosing device used in the new Children’s Panadol 1-5 Years suspensions until a final decision is made by the Court.

GlaxoSmithKline (GSK) is disappointed with the decision made on May 28 2013 by the Federal Court (Justice Rares), to grant an interim injunction over the dosing device used in the new Children’s Panadol 1-5 Years suspensions until a final decision is made by the Court.

GSK reassures our valued customers that there is no safety risk associated with any Children’s Panadol product as a result of this injunction.

GSK denies the allegations of patent infringement on the dosing device and looks forward to a successful resolution of the proceeding when all the evidence becomes available.

The dosing device consists of a neck plug in the bottle and a syringe that fits into the neck plug to withdraw liquid.

GSK is working on an alternative dosing device to minimise any disruption to the availability of new Children’s Panadol 1-5 Years suspensions.

The injunction relates to the new Panadol Children’s 1-5 Years suspension products only. Panadol Children’s Baby Drops, Panadol Children’s 5-12 Years Elixir and the new Panadol Children’s 5-12 Years suspensions are not impacted by this injunction. A healthcare professional should be consulted for advice to determine what other Panadol Children’s product may be appropriate for use if the new Children’s Panadol 1-5 Years product is not available.

When using Children’s Panadol® ALWAYS READ THE LABEL. Use only as directed. For the temporary relief of pain and fever. Incorrect use could be harmful. Consult your healthcare professional if symptoms persist. CHILDREN’S PANADOL is a registered trade mark of the GlaxoSmithKline group of companies.

When using Panadol® ALWAYS READ THE LABEL. Use only as directed. For the temporary relief of pain and fever. Incorrect use could be harmful. Consult your healthcare professional if symptoms persist.

Panadol® is a registered trademark of the GlaxoSmithKline group of companies.

For more information please visit the latest updates on the Children’s Panadol website www.childrenspanadol.com.au